Table 1 Main features of randomised clinical trials of epoetin beta in patients with cancer
Study | Design and no. of patients (epoetin beta/control) | Diagnosis | Epoetin beta dosage and duration of therapy | Control | Cancer treatment |
|---|---|---|---|---|---|
o, pg n=83/37 | Ovarian cancer, Hb <13 g/dl | 150 or 300 IU/kg 3 × week × 6 months | Standard therapy | Chemotherapy | |
o, pg n=95/49 | MM, NHL, CLL; transfusion-dependent, Hb<10 g/dl | 2000–10 000 IU/day titrated or 10 000 IU/day fixed dosage × 24 weeks | Standard therapy | Chemotherapy | |
db, pc, and pg n=28/26 | Resectable rectal cancer; Hb⩾12.5 g/dl (men), ⩾12 g/dl (women) | 200 IU/kg daily × 11 days | Placebo | Surgery | |
db, pc n=52/57 | Colorectal cancer suitable for hemicolectomy, Hb >8.5–13.5 g/dl | 20 000 IU/day × 10–15 days | Placebo | Surgery | |
Data on file (Study MF4266) | o, pg n=10/10 | AML | 10 000 IU/day, then weekly or twice weekly × ⩽30 weeks | Standard therapy | Chemotherapy |
o, pg n=117/29 | MM, NHL, CLL; transfusion-independent, Hb⩽11 g/dl | 1000, 2000, 5000, or 10 000 IU/day × 8 weeks | Standard therapy | Chemotherapy | |
pg n=114/104 | Solid organ tumours, Hb ⩽11 g/dl | 5000 IU/day × 12–24 weeks | Standard therapy | Chemotherapy | |
o, pg n=131/128 | Malignant disease, Hb⩽11 g/dl | 150 IU/kg 3 × week adjusted for Hb response × 12 weeks | Standard therapy | Chemotherapy | |
pc, db, and pg n=170/173 | MM, NHL, CLL; transfusion-dependent and epo-deficient, Hb⩽10 g/dl | 150 IU/kg 3 × week adjusted for Hb response × 16 weeks | Placebo | Chemotherapy |
